SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001493152-21-005141
Filing Date
2021-03-02
Accepted
2021-03-01 20:35:00
Documents
5
Period of Report
2021-03-01

Document Format Files

Seq Description Document Type Size
1 form6-k.htm 6-K 17773
2 ex99-1.htm EX-99.1 16720
3 ex99-2.htm EX-99.2 16430
4 ex99-1_001.jpg GRAPHIC 15963
5 ex99-2_001.jpg GRAPHIC 15963
  Complete submission text file 0001493152-21-005141.txt   96258
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 6-K | Act: 34 | File No.: 001-40101 | Film No.: 21700745
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences